Pharmacokinetic study of K-877 in patients with Primary biliary cholangitis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223672

Enrollment

Registered

2017-10-05

Start date

2017-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary biliary cholangitis

Interventions

investigational material(s) Generic name etc : Pemafibrate INN of investigational material : Pemafibrate Therapeutic category code : 218 Agents for hyperlipidemias Dosage and Administration for Invest

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Primary biliary cholangitis

Exclusion criteria

Exclusion criteria: Person who has liver cirrhosis

Design outcomes

Primary

Measure	Time frame
pharmacokinetics Plasma concentrations and pharmacokinetics parameters of K-877 Central laboratory test	—

Secondary

Measure	Time frame
pharmacokinetics Plasma concentrations and pharmacokinetics parameters of K-877 metabolites Central laboratory test	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026